



Re: Prognosis of prostate cancer and prostate – specific antigen levels

Beuy Joob ¹, Viroj Wiwanitkit ²

¹ Sanitation 1 Medical Academic Center, Bangkok Thailand; ² Honorary professor, Dr DY Patil University, Pune, India

To the editor,

We read the publication on “Prognosis of patients with prostate cancer and middle range prostate – specific antigen (PSA) levels of 20 – 100 ng / mL” with a great interest (1). Iwamoto et al. noted that “PSA is a useful biomarker for predicting prognosis at levels between 20 and 70 ng / mL (1)” and “When the PSA level reaches approximately 70 ng / mL, prognosis might bottom and reach a plateau (1)”. We would like to share ideas on this report. We agree that there might be a plateau phenomenon in case of high PSA level. Nevertheless, we should also be aware on the possible false negative result in patients with low PSA level (2). As an immunological test, the prozone effect is possible and this might lead to aberrant low PSA level (3). In that case, the prognosing might be affected.

CONFLICT OF INTEREST

None declared.

REFERENCES

1. Iwamoto H, Izumi K, Kadono Y, Mizokami A. Prognosis of patients with prostate cancer and middle range prostate – specific antigen levels of 20 – 100 ng / mL. *Int Braz J Urol.* 2019;45:61-7.
2. Basuyau JP, Leroy M, Brunelle P. Determination of tumor markers in serum. Pitfalls and good practice. *Clin Chem Lab Med.* 2001;39:1227-33.
3. Akamatsu S, Tsukazaki H, Inoue K, Nishio Y. Advanced prostate cancer with extremely low prostate-specific antigen value at diagnosis: an example of high dose hook effect. *Int J Urol.* 2006;13:1025-7.

Correspondence address:

Beuy Joob, MD,
Sanitation 1 Medical Academic Center, Bangkok Thailand
E-mail: beuyjoob@hotmail.com

ARTICLE INFO

Beuy Joob

<https://orcid.org/0000-0002-5281-0369>

Int Braz J Urol. 2019; 45: 645-645

Submitted for publication:
December 21, 2018

Accepted after revision:
December 24, 2018

Published as Ahead of Print:
March 20, 2019